Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Takahiro Kojima(Aichi Cancer Center), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Manali Bhave(Northwestern University), Alexander I. Spira(Virginia Cancer Specialists), Alexandra Drakaki(University of California, Los Angeles), Benjamin Garmezy(Sarah Cannon), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Takahiro Kogawa(The Cancer Institute Hospital), Aaron Lisberg(APLA Health), Yoshiaki Kaga(Daiichi Sankyo (United States)), Jeannie Hoffman-Censits(Johns Hopkins University), Mohamad A. Salkeni(Virginia Cancer Specialists), Xīn Gào(Qingdao University), Omar Alhalabi(The University of Texas MD Anderson Cancer Center), G. Klauss(Daiichi Sankyo (United States)), Yasuyuki Kakurai(Daiichi-Sankyo (Japan))
Cited by 15
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k